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Electroneurophysiological evaluation in children and adolescents  
with collagen diseases. 
 
INTRODUCTION 
 The central and the peripheral nervous systems are 
often affected in patients with connective tissue 
diseases and sensorimotor neuropathies have been 
reported in patients with known or suspected 
connective tissue diseases 1. 
Original article 
Background: Sensorimotor neuropathies have been reported in patients with 
known or suspected connective tissue disease. It is often difficult to diagnose 
early neuropathies, and the study of the peripheral neuromuscular system is 
often made difficult by symptoms resulting from pain in the joints and 
limitation of movement.  
Objective: We aimed to investigate the central and peripheral nervous systems 
involvement in patients with pediatric- onset SLE and juvenile rheumatoid  
arthritis through clinical assessment and  neurophysiological studies (motor 
nerve conduction velocity (MNCV) of the tibial nerve bilaterally and 
somatosensory evoked potentials (SSEPs) of the median nerve bilaterally) and 
to study their relation to clinical data and laboratory investigations. 
Methods: Nineteen patients with SLE (mean age 14.47± 3.94 years)and fifteen 
JRA patients (mean age 13.39±3.9 years) were included in the study. Ten 
healthy, matched subjects served as the control group. In addition to clinical 
assessment, including complete neurological and psychiatric evaluation, 
different investigative tools needed for diagnosis as well as assessment of 
systemic involvement and the degree of activity, were implemented. Both 
patients and control groups were subjected to neurophysiological studies 
(Motor nerve conduction velocity (MNCV) of tibial nerve bilaterally and 
Somatosensory evoked potentials (SSEPs) of the median nerve bilaterally). 
Results: Definite manifestations of neuropsychiatric involvement attributable 
to SLE was diagnosed in 37% of SLE patients. Of the SLE patients, 10.5% had 
abnormal MNCV on the right side, while Erb-N13 interpeak latencies were 
prolonged in 10.5% and 31.5% of the median nerves studied on the right and 
left sides, respectively, and N13-N20 was prolonged in 21% and 31.5%, 
respectively. Neither hypertension nor renal involvement significantly affected 
the studied parameters; however, SLE patients with cutaneous vasculitis 
showed slower MNCV of tibial nerve and prolonged Erb-N13 intervals on both 
sides. Erb-N13 and N13-N20 (on the right side) were positively correlated to 
the disease activity index (SLE-DAI). Of the JRA patients, 6% had slowed 
nerve conduction of right tibial nerve, while the interpeak latencies of Erb-
N13 were prolonged in  6.6% and 13.3% on the right and left sides, 
respectively and N13-N20 was prolonged in 6.6% and 20%, respectively. Erb- 
N13 (on the right side) was negatively correlated to the cumulative dose of 
steroids.  
Conclusion: Our study revealed that sensorimotor neuropathies are often 
more common than expected in patients with collagen disease. Early 
subclinical neuropathies may be difficult to diagnose where symptoms from 
joint pain may mask the diagnosis. Widespread vasculitis including vasculitis 
of the vasa nervora may be the underlying pathology, which stresses the value 
of steroids in treatment.  
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In systemic lupus erythematosus (SLE), 
neurological involvement is common  and 
neuropsychiatric lupus erythematosus (NPLE) is 
recognized to occur in a significant percentage of SLE 
patients and to be a leading cause of morbidity and 
mortality 2. However, manifestations of the peripheral 
nervous system (PNS) involvement seem to be less 
prevalent and not so well characterized as compared to 
the central nervous system (CNS) 3. 
In juvenile rheumatoid arthritis (JRA), 
neurological disorders are reported to occur in 10-15% 
4. The nervous system may be involved by 
compression neuropathy (e.g. carpal tunnel syndrome), 
peripheral neuropathy, or occasionally cervical cord 
compression 5.  
It is often difficult to diagnose these slight or early 
neuropathies, and the study of the peripheral 
neuromuscular system is often made difficult by 
symptoms resulting from pain in the joints and 
limitation of movement. It is nevertheless possible by 
means of electroneurophysiological studies to show 
objectively the existence and distribution of even 
subclinical neuropathies, and give an idea about central 
nervous system affection 6.   
The aim of the study was to investigate the central 
and peripheral nervous systems’ involvement in 
patients with pediatric-onset SLE and JRA through 
clinical examination and neurophysiological studies 
namely motor nerve conduction velocity (MNCV) of 
the tibial nerve bilaterally and somatosensory evoked 
potentials (SSEPs) of the median nerve bilaterally and 




This study was a case-control one carried out at the 
Pediatric Allergy and Immunology Outpatient Clinic, 
Children’s Hospital, Ain Shams University. It included 
34 patients with SLE and JRA, who were attending the 
clinic regularly. 
The patients were divided into two groups: 
Group I: 
It included 19 patients with pediatric-onset SLE 
fulfilling the 1982 American Rheumatism Association 
Revised Criteria for diagnosis of SLE 7. They were all 
females, their ages ranged from 12-18 years, with a 
mean age of 14.47 ± 3.94 years and a mean disease 
duration of 5.5 ± 4.15 years. 
Group II: 
It included 15 patients with JRA fulfilling the 1987 
American Rheumatism Association Revised Criteria 
for diagnosis of rheumatoid arthritis 8, with a male to 
female ratio of 7:8; their ages ranged from 7-18 years, 
with a mean age of 13.3 ± 3.9 years, and a mean 
disease duration of  5 ± 3.9 years. 
Exclusion criteria: 
Patients with other causes of peripheral neuropathy 
such as diabetes mellitus, genetically determined 
neuropathy, and chronic abuse of drugs, apart from 
those prescribed for JRA and SLE. 
Control group (Group III): 
A group of 10 clinically healthy children were selected 
from the same general population to which the patients 
belong; their ages ranged from 6 to18 years, with a 
male to female ratio 4:6. 
Clinical evaluation 
Activity of SLE was measured by the Disease Activity 
Index (SLE-DAI) score 9. 
Neuropsychiatric SLE (NPLE) was defined when a 
significant and unequivocal change in the baseline 
neurological and/or psychiatric function was identified 
by history and physical examination 10. Evidence of 
cutaneous vasculitis is included if any of the following 
skin lesions were present: purpura, ulcers, 
subcutaneous nodules or livedo reticularis 10. 
Laboratory investigations 
Including measurement of C3, C4, ANA and anti-
DNA, as well as complete blood count (CBC), ESR, 
complete urine analysis, liver and kidney function 
tests.   
Neurophysiological studies 
All the patients and controls were subjected to motor 
nerve conduction velocity (MNCV) study of the tibial 
nerve bilaterally and somatosensory evoked potentials 
study (SSEPs) of the median nerve bilaterally  
• MNCV of the tibial nerve : 
The apparatus used was counter point MK2 (Dantec, 
USA). The bipolar stimulator is placed on the 
anatomical sites of posterior tibial nerve. A maximal 
stimulus that can be tolerated by the patient without 
eliciting muscle artifact was applied; distance between 
site (1) and (2) is measured in cm, then MNCV is 
calculated. MNCV was considered abnormal if the 
value was two or more SD below the mean control 
values. 
• SSEPs of the median nerve: 
The apparatus used was counterpoint MK2 (Dantec, 
USA). Recording active and reference electrodes was 
put in 3 channels: 
1. Epi-Epc channel: (Erb’s point ipsilateral-Erb’s point 
contralateral).  
2. C5SP-Fz channel: (fifth cervical spinous process -
mid-frontal zone). 
3. Cc-Fz channel: (contralateral somatosensory cortex- 
mid-frontal zone).  
The grounding electrode was placed on the arm 
just above the stimulating electrode. A series of 
negative potentials were recorded from Erb’s point 
(N9), 5th cervical spine (N13), and scalp (N20) using a 
bipolar stimulating electrode placed on the median 
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nerve 1cm proximal to the wrist crease (between 
tendon of flexor carpiradialis and palmaris longus). 
The stimulus wave was square pulse 0.2 msec in 
duration at a rate of 1.5 Hz and delivered with 
sufficient intensity to cause thumb twitch.  
The SSEPs from upper limbs were considered 
abnormal if the following occur: 
1. Prolonged N13-N20 inter-peak latency (IPL) i.e. 
central conduction time (CCT) beyond 2SD of the 
mean value of the control group. 
2. Prolonged Erb-N13 inter-peak 
latency beyond 2SD of the mean 
value of the control group 11. 
Statistical methods 
The methods of statistical analysis of the collected data 
were the following: 
1. Mean (x) and standard deviation 
(SD). 
2. The student t-test of significance 
for comparison between the mean 
of the different groups of patients. 
3. Mann Whitney test (Z test) to 
compare between non parametric 
data with wide variability and 
high standard deviation. 
4. Linear regression analysis: the 
correlation coefficient. 
5. Chi-square was used for categorial variables to test 
differences between groups. 
 
RESULTS 
SLE group: On the basis of history and neurological 
assessment, definite symptoms of neuropsychiatric 
involvement attributable to SLE disease were found in 
7 of the patients (37%), hence considered as affected 
by NPLE. Neuropsychiatric symptoms included: 
picture suggestive of peripheral neuropathy (numbness, 
weak hand grip) in 6 patients (86%), stroke in two 
(28%), seizures in one (14%), anxiety in one (14%), 
and depression in one (14%).  
Six patients (31.5%) were considered as having 
lupus nephritis (persistent proteinuria more than 0.5 
gm/dl and/ or cellular casts (red blood cell, 
hemoglobin, granular, tubular or mixed), of whom 2 
patients had impaired renal function (Table 1). The 
SLEDAI score ranged between 12 and 46, with a mean 
of 19.5 ± 8.6.  
 
MNCV of the tibial nerve bilaterally: 
Of the patients with SLE, two (10.5%) had abnormal 
MNCV (>2 SD below the mean control value) on the 
right side (Table 2).  
The mean values of MNCV of the tibial nerve  
were lower in patients with SLE, significantly so in 
right tibial nerve (mean value: 44.3±4.0 m/sec in SLE 
patients compared to 47.8±4.3 m/sec in the control) 
(t=2.16, p<0.05)  (Fig 1). 
Though there was no significant difference in the 
MNCV when comparing patients with renal affection 
or with hypertension to those without, SLE patients 
with cutaneous vasculitis showed lower mean values of 
MNCV of tibial nerve bilaterally (42.7±2.79, and 42.8 
± 2.85 on the right and left sides, respectively) , with a 
statistically significant difference (t=3.7, p= 0.0018) on 
the left side when compared to those without cutaneous 
vasculitis (46.01±4.59 and 47.68±3.1) (Fig 2). On the 
other hand, SLE patients without neuropsychiatric 
symptoms had a significantly lower mean value of 
MNCV of tibial nerve on the left side (43.83± 3.26 
m/sec) compared to the symptomatic group 
(46.64±4.29 m/sec) (t=2.19, p<0.05). There was a 
negative correlation between MNCV of left tibial 
nerve and duration of illness  (r = -0.52, p< 0.05), as 
shown in Figure (3). 
 
Table (1): Descriptive data of SLE patients (n=19)  
Sex (f/m) 19/0 
Age (years)        Mean ± SD 14.47 ± 3.94 
Age at onset (years) 
                           Range      
                           Mean ± SD 
 
7-16 
10.95 ± 2.3 
Disease duration (years) 
                           Range     
                           Mean ± SD 
 
1-13 
5.53 ± 4.15 
1BHypertension                 n(%) 7/19 (37%) 
2BCutaneous vasculitis       n(%) 10/19 (53%) 
Neuropsychiatric lupus   n(%) 19.53 7 (37%) 
Renal involvement        n(%) 6/19 (31.5%) 
SLEDAI score 
                            Range     
                            Mean ± SD  
 
12-46 
19.54 ± 8.55 
Cumulative dose of steroids (mg/m2) 
                             Range 
                             Mean  





Cytotoxic therapy         n(%) 5/19 (26%) 
 
 
Table (2): The frequency of abnormalities in 
absolute values of electroneurophysiological studies 
(>2SD of control values)  









































SSEPs of the median nerve bilaterally: 
With regards to the SSEP parameters, Erb-N13 
interpeak latencies were prolonged in 10.5% and 
31.5% of the median nerves studied on the right and 
left sides, respectively, while the central conduction 
time (N13-N20) was prolonged in 21% and 31.5%, 
respectively (Table 2). The results of our study 
revealed no prolongation in the mean values of any 
SSEPs interpeak latencies in the SLE group when 
compared to the control group. 
Neither hypertension nor renal involvement 
significantly affected the SSEPs parameters in SLE 
patients. However, SLE patients with cutaneous 
vasculitis showed a significant prolongation of Erb-N13 
interval on right side  and left sides (3.61±0.74 and 
2.31±1.36 m.sec, respectively) compared to those 
without (3.03± 0.33 and 3.89±1.29) (t=2.14 and 2.58, 
respectively, p<0.05) (Table 4). 
SLE patients exhibiting neuropsychiatric 
symptoms showed a significant prolongation of the 
mean value of Erb-N13 on the left side (3.99±1.24 
m.sec) compared to those without (2.52 ±1.45) (t= 
2.24, p<0.05)(Table 3). 
 
Table (3): Comparison  between SLE patients with 
neuropsychiatric symptoms (NPLE) and those 
without (no-NPLE) as regards MNCV of tibial 
nerve bilaterally.                                 























a p< 0.05 (significant). 
Rt. = right, Lt. = left, n.= nerve. 
 
There was a positive correlation between Erb-N13 
and N13-N20 on the right side and SLE DAI score (r = 
0.52 and p= 0.02, and r = 0.54 and p= 0.01 
respectively) (Fig 4). 
 
JRA patients 
Demographic characteristic of JRA patients  
Only two patients (13%) gave positive history 
suggestive of peripheral neuropathy (numbness and 
weak hand grip), however none had abnormal findings 
on clinical examination or in the results of the studied 
parameters (Table 5). 
 
MNCV of tibial nerve 
Of the patients with JRA, one patient (6%) had slowed 
nerve conduction of the  right tibial nerve >2SD of the 
control (Table 2), nevertheless, there was no 
significant difference in the mean values of MNCV of 
tibial nerve (bilaterally) between JRA patients and 
control group.  
 
SSEPs of median nerve bilaterally 
Regarding SSEPs of median nerve evaluation of JRA 
patients, the interpeak latency of Erb-N13 was 
prolonged in  6.6% on the right side and 13.3% on the 
left side, while N13-N20  was prolonged in 6.6% and 




Table (4): Comparison between SLE patients with 
cutaneous vasculitis and those without as well as 
between SLE patients with neuropsychiatric 
symptoms (NPLE) and those without (no-NPLE) as 
regards parameters of SSEPs of median nerve. 
SSEPs 















































6.82±1.79 6.72±1.56 7.25± 1.64 
5.96± 
1.39 




Table (5): Descriptive data of JRA patients (n=15): 
Sex (f/m) 8: 7 
Age (years)                     Range 
                                        Mean ± SD 
7-18 
13.3 ± 3.9 
Age at onset (years)        Range      
                                        Mean ± SD 
2.5-14 
8.3 ± 4.5 
Disease duration (years) Range     
                                        Mean ± SD 
1-14 
5 ± 3.9 
Hypertension                   n (%) 3/15 (20 %) 
History suggestive of peripheral 
neuropathy                      n (%) 
2/15 (13%) 
Steroid therapy                n (%) 10/15 (67%) 
El-Gamal et al. 
18 
Cumulative dose of steroids (mg/m2) 
                    Range 
                    Mean ±  





3BCytotoxic therapy            n (%) 6/15 (40%) 
 
The results of comparison between JRA and 
control groups revealed no significant prolongation. 
Similarly, patients with different forms of disease- 
onset did not show difference in any of the studied 
parameters.   
No significant correlation was found between the 
neurophysiological studies and the duration of illness. 
However, a significant negative correlation was found 
between Erb- N13 (on the right side) and cumulative 






p<0.05 on the right side. 
 
Fig(1): Comparison between SLE patients and the 







p< 0.05 on the left.  
 
Figure (2): Comparison between SLE patients with 
cutaneous vasculitis and those without as regards 
















Figure (3): Correlation between  MNCV of left 

















Figure (4): Correlation between Erb-N13 of the 
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Figure (5): Correlation between Erb-N13 interval of 
SSEPs of right median nerve and cumulative dose 




Studying the neurologic and psychiatric 
symptomatology in lupus patients, 36% gave positive 
symptoms and they were referred to as 
neuropsychiatric lupus (NPLE), this is in agreement 
with the studies of both Steinlein et al. 12 and Fierro et 
al. 10, in which NPLE patients represented 43% and 
42% of the studied groups, respectively. However, a 
much higher percentage was found in the study of 
Schmutzler and colleagues 13, in which NPLE 
represented 71%. 
The most prevalent neuropsychiatric symptoms in 
our study were symptoms suggestive of peripheral 
neuropathy (86%), and seizures (78%), while stroke, 
depression and anxiety were reported each in 14% of 
patients. This is in agreement with Fierro 9 and 
associates’ study 10 on lupus patients, in which 
symptoms of peripheral neuropathy were also the most 
prevalent symptoms (46%), followed by seizures 
(33%), organic brain syndrome (27%), affective 
disorders (13%) and lastly stroke in 7%. 
Neurophysiological evaluation of SLE patients in 
our study revealed  that MNCV of tibial nerve was 
delayed (>2SD of the control) in 10.5% of patients. 
Statistical comparison of MNCV of tibial nerve 
revealed that their mean values were delayed in SLE 
patients bilaterally when compared to the control 
group, significantly so on the right side. These result 
were in agreement with Omdal et al. 3, and Sivri et al. 
14 who reported delay in the NCV of tibial nerve in 
15% and 23.6% of their patients, respectively. 
In our study SLE patients suffering from cutaneous 
vasculitis showed delay in the mean values of MNCV 
of the tibial nerve bilaterally when compared to SLE 
without cutaneous vasculitis, with a significant  
difference on the left side. This association was noticed 
by McNiholl et al. 15, who documented that SLE 
patients with neurophysiological impairment had a 
higher frequency of vasculitis, as well as the presence 
of vasculitis increased the risk of acquiring new 
neurophysiological abnormalities. 
It is of value also to document that the 
asymptomatic SLE group showed a significant delay in 
the mean values of MNCV of left tibial nerve when 
compared to the symptomatic group. This proves that 
neurophysiological studies can frequently evidentiate 
subclinical rather than clinical neurological 
dysfunction in patients with SLE as previously 
reported by Fierro and colleagues 10.  
When correlating MNCV of tibial nerve with 
clinical data of our lupus patients, there was a negative 
correlation between MNCV on left tibial nerve and 
duration of illness. This may represent increased 
exposure to circulating immune complexes, anti-
endothelial and antineuronal antibodies or to other non 
immune factors as infection, drugs or metabolic 
derangement. By contrast, in their two studies, Straub 
and coworkers 1 and Sivri and colleagues 14, found no 
correlation between NCV and disease duration in 
lupus.  
In our study, the mean values of SSEPs interpeak 
latencies  did not show any significant difference in 
SLE patients in comparison to the controls. However, 
Erb-N13 latencies were increased above 2SD of the 
control range in 10.5% on the right side and 31.5% on 
the left side and N13-N20 interval was prolonged in 
21.3% on the right side and 31.5% on the left side. By 
comparison, Fierro et al. study 10, who studied SSEPs 
only on the right median nerve, found that Erb-N13 
interval was increased in 25% and N13-N20 interval was 
increased in 28%, while Sivri et al 14, who studied 
median and tibial nerve somatosensory evoked 
potential (SSEPs) documented 39.5% of studied lupus 
patients showing SSEPs abnormalities. 
Worth noting is the significant association between 
cutaneous vasculitis and prolonged Erb-N13 interval 
bilaterally; this was in agreement with the study done 
by Fierro and coworkers 10. The evidence of cutaneous 
vasculitis can suggest a diffuse systemic vasculitis 
involving the cerebral vessels and vasa-nervora 
supplying peripheral nerves 16. 
The highly significant positive correlation between 
Erb-N13 and N13-N20  intervals (central conduction time) 
on the right side and SLEDAI score proved that 
SLEDAI scoring can be used to judge CNS 
involvement in lupus patients  as previously suggested 
by Straub et al.1.             
JRA is a progressive systemic disease that 
predominately affects the synovial tissues; neurological 
disorders are registered in 10-15% of cases 4. The 
principal neuropathies of RA include nerve 
compression and a mild distal sensory impairment. 
These may be manifested only by parasthesia, burning 
sensation with few objective signs. Patients with 
prominent joint pain may not specifically complain of 
additional symptoms such as weakness and parasthesia, 
which suggest neuropathy6. 
On the basis of history and clinical neurological 
examination, our study revealed that only two (13%) of 
our patients with JRA gave neuropathic symptoms, 
nevertheless careful clinical examination did not 
support the diagnosis of neuropathy. The MNCV of 
tibial nerve bilaterally revealed no significant 
difference when compared to the control group, 
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however only one patient (6%) had slowed nerve 
conduction on the right tibial nerve (>2SD of the 
controls). 
In 1986, Puusa et al. 17 studied 129 children with 
JRA and reported no clinically manifested neuropathy 
among them. By contrast, Sivri and Guler-Uysal 18, 
who studied adult patients with RA, documented that 
symptoms and signs of neuropathy are fairly common 
in RA. In their study, 6% of patients gave symptoms 
and signs of carpal tunnel syndrome, while 18% had 
mononeuritis multiplex. Our results are also much 
lower than the results of Chang et al.19, who found 44% 
acute-subacute mononeuritis multiplex in his RA 
patient group. The difference from our results may be 
due to the difference in the age of the included 
subjects, where these studies were conducted on adults. 
The suggestion that peripheral neuropathy is more in 
adult patients with RA than in JRA, may be explained 
by Puusa et al. 17, who documented that arteritis which 
involves the arteries supplying the peripheral nerves 
(vasa-nervora) do not typically occur in JRA even after 
long period of illness which may be explained by the 
young age of onset, the prompt and effective initiation 
of treatment and perhaps a somewhat milder and 
different clinical picture, compared to adult patients. 
As regards SSEPs of median nerve evaluation of 
JRA patients, though there was no significant 
difference in the interpeak latencies between the 
patients and controls, Erb-N13 and N13-N20 were 
prolonged in  6.6% on the right side and 13.3% and 
20% respectively on the left side. 
Few studies have investigated the effect of RA on 
early somatosensory evoked potential, which reflects 
spinal cord function and of value in detecting early, 
sub-clinical lemniscal tract damage 20. Katz et al. 21 
reported that 10 out of 15 RA patients (67%) had 
abnormalities in SSEPs of the median nerve. Lower 
percentages were found in the study performed by 
Naglic et al. 4, who studied 56 patients with RA, all 
were females and with a mean age of 52 years. They 
showed increasing N13-N20 difference registered in 
18%.The difference from our results may again be 
explained by the different age groups studied in each. 
In agreement with Sivri and Guler- Uysal study 18, 
our study found that neither the mode of disease- onset, 
nor the type of therapy or the duration of disease did 
affect any of the  studied SSEPs parameters.  
However, it is worth reporting the significant 
negative correlation between cumulative dose of 
steroids and Erb-N13 on right median nerve (pathway 
from brachial plexus till cervical spinal cord). This 
implies that the use of corticosteroids in the treatment 
of neuropathies associated with systemic vasculitis is 
very efficient 22. 
In conclusion, our study revealed that sensorimotor 
nerves are often more affected than expected in 
patients with connective tissue disease. Though clinical 
assessment remains the corner stone of diagnosis, yet 
by itself, evidently results in under-diagnoses of 
nervous system involvement especially that early 
subclinical neuropathies may be difficult to diagnose 
on clinical basis where symptoms from joint pain and 
limitation of movements may mask the diagnosis. 
Widespread vasculitis including vasa nervora 
supplying peripheral nerves may be the underlying 
pathology which stresses the value of steroids in the 
treatment of neurological manifestations due to 
vasculitis. 
We thus recommend routine neurophysiological 
evaluation of patients with SLE and JRA to detect 
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